Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 5974

In 2020, Houston-based company Axiom Space got a NASA contract of its own, worth up to $140 million, to deliver at least one habitable private module to the ISS. Axiom plans to launch its first element to the orbiting lab in late 2024, then send several more up over the next few years. Eventually, the connected Axiom modules will detach from the ISS, leaving their natal nest like a bird that has learned how to fly.

Axiom has other irons in the spaceflight fire as well. For instance, the company has booked four commercial crewed flights to the ISS with SpaceX, the first of which is scheduled to launch in February.

Read more | >

More than two years after the rocket’s last launch, SpaceX appears to have finally decided to give at least one of two surviving Falcon Heavy Block 5 cores a new lease on life as a Falcon 9 booster.

Known as B1052, the Falcon Heavy side core or booster debuted in April 2019 as part of the first flight of the rocket’s Block 5 variant, successfully launching Saudi Arabia’s large Arabsat 6A communications satellite to an almost 90,000 km (56,000 mi) transfer orbit. Following in the footsteps of the first Falcon Heavy, the first Block 5 vehicle repeated its predecessor’s iconic double-landing back at Cape Canaveral. Just 74 days later, both Falcon Heavy Block 5 side boosters B1052 and B1053 launched again, this time supporting the US military’s long-delayed STP-2 rideshare and qualification mission.

Read more | >

Many intractable diseases are the result of a genetic mutation. Genome editing technology promises to correct the mutation and thus new treatments for patients. However, getting the technology to the cells that need the correction remains a major challenge. A new study led by CiRA Junior Associate Professor Akitsu Hotta and in collaboration with Takeda Pharmaceutical Company Limited as part of the T-CiRA Joint Research Program reports how lipid nanoparticles provide an effective means for the delivery to treat Duchenne muscular dystrophy (DMD) in mice.

Last year’s Nobel Prize for Chemistry to the discoverers of CRISPR-Cas9 cemented the impact of genome editing technology. While CRISPR-Cas9 can be applied to agriculture and livestock for more nutritious food and robust crops, most media attention is on its medical potential. DMD is just one of the many diseases that researchers foresee a treatment using CRISPR-Cas9.

“Oligonucleotide drugs are now available for DMD, but their effects are transient, so the patient has to undergo weekly treatments. On the other hand, CRISPR-Cas9 effects are long lasting,” said Hotta.

Read more | >

In the history of space exploration, a handful of missions have set new records for ruggedness and longevity. On Mars, the undisputed champion is the Opportunity rover, which was slated to run for 90 days but remained in operation for 15 years instead! In orbit around Mars, that honor goes to the 2001 Mars Odyssey, which is still operational 20 years after it arrived around the Red Planet.

In deep space, the title for the longest-running mission goes to the Voyager 1 probe, which has spent the past 44 years exploring the Solar System and what lies beyond. But in Earth orbit, the longevity prize goes to the Hubble Space Telescope (HST), which is once again fully operational after experiencing technical issues. With this latest restoration of operations, Hubble is well on its way to completing 32 years of service.

The issue began at 01:46 A.M. EDT (10:46 P.M. PDT) on October 23rd, when NASA reported that the venerated space telescope was sending error codes, which indicate the loss of a specific synchronization message. This message provides timing information that Hubble’s instruments use to respond to data requests and commands correctly. The same error codes were issued two days later, indicating multiple losses of synchronization messages and triggering Hubble to enter safe mode.

Read more | >

Amid growing international concern about China’s human rights record, an unofficial tribunal in London has ruled China has committed genocide against the Uyghur people in Xinjiang.

Erbakit Otarbay is one of an estimated one million Kazakhs, Uyghurs and other ethnic minorities held in China’s detention camps as part of a mass incarceration programme. He gave evidence in the tribunal.

He was arrested in 2017, accused of downloading WhatsApp, which is blocked in China, and of watching videos about Islam.

Erbakit told the BBC how he was subjected to forced labour, indoctrination and violent beatings.

Continue reading “Held in chains for using WhatsApp — BBC News” | >

Gene therapy is a powerful developing technology that has the potential to address myriad diseases. For example, Huntington’s disease, a neurodegenerative disorder, is caused by a mutation in a single gene, and if researchers could go into specific cells and correct that defect, theoretically those cells could regain normal function.

A major challenge, however, has been creating the right “delivery vehicles” that can carry genes and molecules into the that need treatment, while avoiding the cells that do not.

Now, a team led by Caltech researchers has developed a gene-delivery system that can specifically target cells while avoiding the . This is important because a gene therapy intended to treat a disorder in the brain, for example, could also have the side effect of creating a toxic immune response in the liver, hence the desire to find delivery vehicles that only go to their intended target. The findings were shown in both mouse and marmoset models, an important step towards translating the technology into humans.

Read more | >